Allergan plc (AGN, Financial) (3.4% of net assets as of December 31, 2015) (AGN – $312.50 – NYSE) markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. A combination with Pfizer is pending and should close sometime this year.
From the GAMCO Global Growth Fund fourth quarter 2015 commentary.
